MedPath
FDA Approval

Octreotide

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
June 15, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Octreotide(100 ug in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC

023648251

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Octreotide

Product Details

NDC Product Code
63323-376
Application Number
ANDA077457
Marketing Category
ANDA (C73584)
Route of Administration
SUBCUTANEOUS, INTRAVENOUS
Effective Date
May 11, 2021
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACTQuantity: 7 mg in 1 mL
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACTQuantity: 2 mg in 1 mL
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACTQuantity: 2 mg in 1 mL
Code: 75R0U2568IClass: ACTIMQuantity: 100 ug in 1 mL

Octreotide

Product Details

NDC Product Code
63323-377
Application Number
ANDA077457
Marketing Category
ANDA (C73584)
Route of Administration
SUBCUTANEOUS, INTRAVENOUS
Effective Date
May 11, 2021
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACTQuantity: 7 mg in 1 mL
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACTQuantity: 2 mg in 1 mL
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACTQuantity: 2 mg in 1 mL
Code: 75R0U2568IClass: ACTIMQuantity: 500 ug in 1 mL
© Copyright 2025. All Rights Reserved by MedPath